Search
CX-052075
go.drugbank.com/drugs/DB31655ApprovedCX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586]
Ibutilide
go.drugbank.com/drugs/DB00308ApprovedIbutilide is a Class III antiarrhythmic agent available in intravenous formulations.
Hydroquinone
go.drugbank.com/drugs/DB09526ApprovedInvestigationalAs a result of these concerns, hydroquinone has been banned in the EU and UK. … Hydroquinone is a topical lightening product found in OTC products, and is used to correct skin discoloration associated with disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention
Mixtures: CREMA CON ACIDO GLICOLICO AL 8%Categories: Compounds used in a research, industrial, or household settingSAR-260301
go.drugbank.com/drugs/DB33608InvestigationalCategories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsRadium Ra 223 dichloride
go.drugbank.com/drugs/DB08913ApprovedInvestigationalRadium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. … As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases.
Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 DichlorideBuspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBuspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. … Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates
Letaxaban
go.drugbank.com/drugs/DB11984InvestigationalLetaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome.
Categories: Factor Xa InhibitorsSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalAs a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.
Cobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalAlthough it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.